A phase 1B open-label clinical trial to expand the characterization of the immune responses to the Merck adenovirus serotype 5 HIV-1 Gag/pol/nef vaccine [V 520] in healthy, HIV-1 uninfected adult participants.
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2013
At a glance
- Drugs V 520 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 09 Sep 2008 Planned end date changed from 1 Sep 2007 to 1 May 2012, as reported by ClinicalTrials.gov.
- 22 Sep 2007 Status changed from initiated to discontinued.